Introduction
============

Tumor-induced osteomalacia (TIO), also known as oncogenic osteomalacia, is a rare paraneoplastic syndrome caused by overproduction of fibroblast growth factor 23 (FGF23) by a tumor. FGF-23 plays a vital role in renal phosphate handling and vitamin D synthesis. Hence, TIO is characterized by hypophosphatemia due to renal phosphate wasting, inappropriately normal or low 1,25 dihydroxy vitamin D, and elevated or inappropriately normal plasma FGF-23. These biochemical alterations eventually result in osteomalacia. Due to its rarity, the diagnosis of TIO is delayed with the average time from onset of symptoms to diagnosis being more than 2.5 years ([@bib1]). As a result, patients often present in a debilitated state with multiple fractures, severe muscle weakness and loss of height due to skeletal deformities. Even with a high index of suspicion, tumor localization remains challenging as the offending tumor may be very small and can be anywhere in the body. Complete tumor resection remains the mainstay of treatment and is known to result in dramatic resolution of symptoms.

The first case of TIO was reported by Robert McCance in 1947 who treated a patient having low phosphorus levels and bone pain with high doses of vitamin D suspecting her to be a case of 'vitamin D resistance'; however, the symptoms did not completely resolve until a tumor found in the femur was removed ([@bib2]). Thereafter, more than 300 cases of TIO have been reported in literature with more than 200 being reported since 2000 ([@bib3]). The most common tumor site is the lower extremity (\>40%) followed by the head and neck region (\>20%) ([@bib4]). There have been several reviews on pathological characters of such tumors but there is no comprehensive review describing clinical characteristics and management of patients with TIO in head and neck region. This article aims to describe a single-center experience with TIO involving the head and neck region followed by a comprehensive clinically oriented review of world literature for the same.

Materials and methods
=====================

Cohort 1
--------

Medical records of patients attending Department of Endocrinology, KEM Hospital, Mumbai who were diagnosed with TIO from January 2005 till August 2018 were reviewed after obtaining approval from Institutional Ethical Committee II, Seth G S Medical college and KEM Hospital, Mumbai. Informed consent for the photographs, publication of their clinical details and/or imaging was taken. Patients diagnosed with TIO involving the head and neck region were identified and reviewed for inclusion. Concurrently, patients diagnosed with TIO in other regions, and patients with secondary TIO ([@bib3]) (including neurofibromatosis, epidermal nevus syndrome, and polyostotic fibrous dysplasia of bone) were excluded from the study.

Diagnosis of TIO was considered in patients presenting with features of hypophosphatemia in absence of relevant family history, evidence of renal phosphate wasting (as demonstrated by low % fractional tubular reabsorption of phosphate (TRP) and tubular maximum for phosphate corrected for glomerular filtration rate (TMP/GFR)) with elevated fibroblast growth factor-23 (FGF-23). Only those patients who had anatomical/functional imaging (CT/MRI or Ga-DOTATATE PET/CT) demonstrating localization of tumor in head and neck region have been included for analysis (*n* = 7).

Biochemical parameters recorded pre-operatively include S. calcium, S. phosphorus, S. alkaline phosphatase (ALP), TMP/GFR, TRP and FGF23 levels, and post-operatively include S. phosphorus and FGF-23 levels. Normal ranges for various parameters at our institute are as follows: S. calcium (9--10.5 mg/dL), S. phosphorus (2.5--5 mg/dL), S. ALP (\<117 U/L), TMP/GFR (age- and sex-adjusted values as recommended by Chong *et al.* ([@bib3])), TRP (\>85%) and C-terminal FGF-23 (0--150 RU/mL). Furthermore, details from imaging studies done for localization (CT or Ga-DOTATATE PET/CT), treatment modality used, and histopathology reports have been included for analysis. For patients having recurrent disease additional information including time of recurrence following primary management, biochemical profile, localization of recurrent disease and secondary modality of treatment used was documented.

Tubular resorption of phosphate was measured from phosphate and creatinine levels in a spot fasting urine and serum samples at baseline before starting phosphate supplements. TMP/GFR was calculated with use of a nomogram reported by Bijvoet *et al.* FGF23 was assessed by enzyme-linked immunosorbent assay (FGF23 (C-terminal) kit, Immunotopics, Inc, San Clemente, CA, USA). The kit has sensitivity, an intra-assay coefficient of variation (CV), and an inter-assay CV of 30 RU/mL, 5 and 7.3%, respectively. Serum 1,25(OH)2 vitamin D was assessed by radioimmunoassay (RIA), using a DIA source RIA CT kit by DIA source Immunoassays, SA, with an intra-assay CV of 4.5--9.3% (at 77.3 and 24.5 ng/L concentrations, respectively) and inter-assay CV of 11.3--12.7% (at 33.4 and 13.6 ng/L concentrations, respectively). Whole-body (head to toe) scanning with two acquisitions were obtained 1--1.5 h post intravenous injection of 74--111 MBq of DOTATATE labeled with 68Ga. 68Ga was obtained from an in-house 68Ge/68Ga generator. Scans were acquired on a GE Discovery STE PET/CT with 128 × 128 matrix size and 3 min per bed position of iterative algorithm time. The numbers of bed positions were dependent on the height of the patient, usually 10--12 per patient. CT scans were obtained on a 64-slice Phillips Brilliance CT scanner, while MRI scans were performed on a 1.5 tesla Siemens Sonata (Henkestrabe, Germany) MR scanner.

Cohort 2
--------

We searched for all original and review articles in PubMed till June 2019 ([Fig. 1](#fig1){ref-type="fig"}). Individual search was carried out for terms 'Tumour-Induced Osteomalacia', 'Oncogenic Osteomalacia', and 'Phosphaturic Mesenchymal Tumour'. All original and review articles published in English were reviewed for inclusion. Only publications describing TIO in head and neck region were included. A secondary search for relevant publications was carried out by handsearching through the reference lists of selected publications. Hence, in addition to the cases described in our series, we reviewed 163 index cases from 109 publications of TIO of head and neck region previously reported in literature. Clinical profile, biochemical investigations, imaging modality used for localization, location of tumor, treatment modalities used, histopathology findings, recurrence and its management, and metastasis if any were noted. Whenever serum levels of calcium, phosphorus, parathyroid hormone (PTH), 1,25 (OH)2 vitamin D3 levels were available in SI units, they were converted to conventional units with online calculators for uniformity in documentation. Serum ALP when available in units/liter only was included for analysis, while values reported in any other units were excluded due to non-availability of a suitable conversion method. Figure 1Flowchart of search strategy and selection of studies for inclusion in systematic review.

Statistical analysis
--------------------

Statistical analysis was performed using SPSS software version 23.0. Mean (±standard deviation ([s.d.]{.smallcaps})) was used for continuous variables when they were normally distributed and median (interquartile range (IQR)) was used for variables with skewed distribution. The difference between categorical variables was analyzed using chi-square test. *P* value \<0.05 is considered significant.

Results
=======

Cohort 1
--------

This cohort includes seven index patients with TIO involving head and neck region. Their characteristics are described in [Table 1](#tbl1){ref-type="table"}. The cohort comprised four males and three females with mean age of 42.7 ± 10.6 years whose tumors were located in paranasal sinuses (*n* = 3), maxilla (*n* = 2), and intra-cranially (*n* = 2). All patients presented with bone pain and muscle weakness, while pathologic fractures (*n* = 4) and local symptoms (*n* = 5) were present in majority of patients. The time lag from onset of symptoms to diagnosis was lengthy (mean: 65.1 ± 50.3 months). In four patients, location of tumor was suspected at initial presentation based on clinical history and examination. Thereafter, tumor location was confirmed with Ga-DOTANOC in two patients, with MRI in one patient and CT in one patient. Three patients were primarily detected on Ga-DOTANOC/DOTATATE PET/CT; one patient had a history of epistaxis elicited retrospectively after tumor localization. Mean tumor size was 3.6 ± 1.3 cm. Except for one patient (who was initially operated at another hospital), pre and post-operative serum phosphorus and FGF-23 levels were available in all patients ([Table 1](#tbl1){ref-type="table"}). Three patients were cured with initial surgery, while four had persistent disease. No recurrence was documented in patients cured initially (*n* = 3) over a mean follow-up of 17 months. Out of four patients with persistent disease, one patient was cured with repeat surgery only, two patients were cured with repeat surgery and external beam radiation therapy (EBRT), and one has stable disease after peptide receptor radionuclide therapy (PRRT). Histopathologic findings revealed phosphaturic mesenchymal tumor mixed connective tissue type (PMTMCT) in four patients, while the remaining three patients had PMT-OF (ossifying fibroma like), hemangiopericytoma, and odontogenic fibroma, respectively. Clinical images of case numbers one, five and six are shown in [Figs 2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"} respectively. Figure 2(Case 1): A 32-year-old female presented with bone pains and multiple fractures for 7 years. On examination, approximately 2 cm-sized round swelling in right upper alveolus was seen (A). Preoperative chest radiograph (image contrast adjusted) showing Looser's zone along lateral border of scapula (arrows) suggestive of osteomalacia (B). Axial contrast-enhanced CT image soft tissue window showing small enhancing lesion in right upper alveolus (arrow) extending from canine to 1st molar tooth causing erosion of right upper alveolus (C). Ga-DOTATATE PET scan showing increased uptake at the level of right maxillary alveolus (arrow) (D). After excision histopathological examination showing tumor comprising of spindle cells with scattered osteoclastic giant cells bearing histologic semblance to giant cell granuloma (odontogenic fibroma) (E) (H&E, 400×). Figure 3(Case 5): A 53-year-old female presenting with pain in bilateral groins and difficulty in walking for 3-year duration. As investigations confirmed the diagnosis of FGF-23-dependent hypophosphatemic osteomalacia, ^68^Ga-DOTATATE PET scan was done to locate the tumor which showed increased uptake in base of skull in left side (dashed arrows) (A). Corresponding axial CT images (B) showing soft tissue density lesion involving occipital bone on left side with erosion of the mastoid and petrous part of adjacent temporal bone. Retromastoid craniotomy with tumor excision was done. Histopathological examination showed hypercellular tumor composed of prominent small blood vessels with areas of hemorrhage (H&E, 200×) (D). Post first surgery repeat ^68^Ga-DOTATATE scan and corresponding CT images showing residual uptake in base of skull in left side (dashed arrows) in the soft tissue density lesion involving occipital bone on left side with erosion of the mastoid and petrous part of adjacent temporal bone (E). After failed second surgery, patient is now having stable disease after two cycles of PRRT. Figure 4(Case 6): A 33-year-old female presenting with pain in bilateral groins, difficulty in walking and multiple fractures for 3-year duration. There was past history of dental surgery for some 'gum swelling'. On examination, there was swelling in right upper alveolar region (A). X-ray right forearm AP view (image contrast adjusted) showing ulnar shaft fracture (B). MRI hip showing bilateral femoral neck insufficiency fractures which was reported as 'bilateral avascular necrosis' (C). Ga-DOTANOC scan showing uptake in the right maxillary tumor (D). CECT PNS axial view showing 3 cm tumor in right maxillary region (E). Patient was cured with right maxillectomy and osseous reconstruction. Histopathology showed tumor composed of cellular connective tissue intermixed with woven bone displaying osteoblastic rimming (i.e. ossifying fibroma-like histology) (H&E, 100×). Table 1Details of cohort 1 patients.Case no.Age/sexLocation of tumorClinical featuresImaging characteristicsS. Phosphorus (mg/dL)FGF-23 (RU/mL) (0--150)Local symptomsFeatures of TIODuration (months)Localization withSize of tumor (cm)Pre-opPost-opPre-opPost-op132/FRight maxillary alveolusSwelling over right alveolusP, F84History and PE1.21.94.3950102246/MLeft petrous tumorEarache, protruding mass from left earP, MW, F156History and PE51.23.3NA118.6360/MLeft ethmoid sinusEpistaxisP, MW, F12Ga-DOTANOC4.70.91.864672.5439/MRight frontal & ethmoid sinusNoP, MW48Ga-DOTANOC2.30.91.03787191553/FBase of the skullNoP, MW36Ga-DOTATATE3.51.5NA725153633/FRight maxillaRight upper gum swellingP, MW, F36History and PE30.6\
x1.3889885736/MRight nasal cavityEpistaxis, nasal obstructionP, MW84History and PE51.94202482**Case no.Surgical managementPersistenceSecond line modalityTotal duration of follow-upStatusHistopathologyProcedureComplete resectionSurgeryRTPRRT**1Infrastructure maxillectomyYes--------48CuredOdontogenic fibroma2Retromastoid craniotomy with left petrosectomyNoYes--Yes--96CuredHemangiopericytoma3FESSNoYesFESS 2 timesIMRT 54 Gy in 30 fractions--36CuredPMTMCT4Frontal craniotomy and excisionNoYesEndoscopic endonasal tumor excision----29CuredPMTMCT5Retromastoid craniotomy with tumor excisionNoYesYes--Yes13PersistencePMTMCT6Right maxillectomyYesNo------12CuredPMT OF like7Endoscopic endonasal tumor excisionYes--------2CuredPMTMCT[^1]

Cohort 2
--------

This cohort consists of 163 index patients from 109 publications. Pertinent data relevant to index patients is provided in [Table 2](#tbl2){ref-type="table"}. Details of clinically relevant parameters are summarized in [Table 3](#tbl3){ref-type="table"}. Tests done using two different methods have been tabulated separately in [Table 3](#tbl3){ref-type="table"}. Due to heterogeneity in reporting of various parameters, the number of cases included (as denominator) have been specified for each parameter. The mean age was 46 ± 14 years with equal male:female ratio. The reported frequency of tumor sites, in descending order, are paranasal sinuses, mandible, intracranial, maxilla, oral cavity and others. Approximately half the patients (44.1%) had evident local symptoms. Bone pain and muscle weakness were most commonly reported. Late complications of hypophosphatemia such as fractures (61%) and bony deformities including kyphosis/scoliosis with resultant height loss (25.7%) were seen in a significant number of patients. Most patients were diagnosed late in their disease course, despite early access to health care, with median duration from symptom onset being almost 4 years. Out of 163 patients, median elevation of FGF-23 up to 3.6 times ULN has been reported in 55 patients with the interquartile range (IQR) being 1.8--6.8 × ULN. The primary treatment modality was surgery in most patients (97.5%). Two patients with intracranial tumors, who declined surgery, were treated with primary EBRT. Also, two patients received immediate post-operative EBRT for prevention of recurrence due to fear of incomplete tumor removal. Table 2Review of published literature on head and neck TIO cases: list of index cases with relevant data.Case no.AuthorAge/sexLocation of tumor\
Duration of symptomsLocalizing imagingFGF-23Persistence/recurrence\
Secondary modalityHPRPre-surgeryPost-surgery1Renton (5)53FLeft ethmoid60X-rayNANANA--Hemangiopericytoma2Sweet (6)25FLeft middle turbinate12CTNANANo--Hemangiopericytoma3Nitzan (7)26MLeft mandibular molar legion24X-rayNANANo--Giant cell tumor4Nomura (8)29MMandible24X-rayNANAPersistenceRT, chemotherapy, 2nd surgery, chemotherapyPMT ossifying fibroma like5Linsey (9)54FRight nasopharynx30CTNANANA--PMTMCT6Shenker (10)55MNeckNANANANANo--PMTMCT7Sheshadri (11)40FEthmoid sinusNACTNANANA--Hemangiopericytoma8Jefferies (12)27FLeft maxillary sinus24CTNANANA--PMT9Weidner (13)39FRight maxillary sinus24CTNANARecurrenceRepeat surgery\
Primitive mesenchymal tumor10Papotti (10)38FNasal cavityNANANANANo--PMTMCT11Harvey (10)32FThyroid144PENANAPersistenceRepeat surgery: partial f/b total laryngectomy f/b RT and continued on medical managementMalignant PMTMCT12Lee (14)66FLeft nasal cavity36CTNANANo--Hemangiopericytoma13Catalano (15)66FRight maxillary and ethmoidal sinusmany yearsCTNANANo--Hemangiopericytoma14Wilkins (16)55MLeft infratemporal mass24CTNANANo--Sinonasal hemangiopericytoma like15David (17)60FRight subfrontal mass18CTNANARecurrenceMedical managementHemangiopericytoma16Kim (18)41MRight upper premolar48PENANANo--Giant cell tumor17Kim (18)32FLeft mandibular molar area96PENANANo--Ossifying fibroma18Avila (19)48MMandible60MRINANANo--Chronic inflammatory tissue with fibrosis and epithelial rests19Yang (20)31FLeft mandible96CTNANANA--PMT-MCT20Gonzalez-Compta (21)69FRight ethmoido-frontal mass216CTNANAPatient died of tumor--PMT21Ohashi (22)43MLeft maxillary sinus14CTNANANA--Hemangiopericytoma22Clunie (23)60FEthmoid sinuses60CTNANARecurrenceMedical managementHemangiopericytoma23Sandhu (24)46MRight ethmoid sinus18CTNANANo--Hemangiopericytoma24Reyes-Mugica (25)9FLeft mandible1.5MRINANANo--PMT-MCT26John (27)54FRight frontal, ethmoidal, sphenoid sinusesNAPENANANAPatient received Immediate RT following surgeryMalignant Schwannoma27Reis-Filho (28)47FCavernous sinus84CTNANANo--PMTMCT28Fuentealba (29)63FMaxillary sinus60CTNANAPersistenceSurgery, RT, embolizationHemangiopericytoma29Ungari (30)24MEthmoidNACTNANANA--Hemangiopericytoma30Folpe (10)29MEthmoid/\
sphenoid sinus24NANANANo--Hemangiopericytoma31Folpe (10)46MEthmoid sinus36NANANARecurrenceRepeat surgeryHemangiopericytoma32Dupond (31)71MLower mandible12FDG-PET199 Ru/mL (N \<100)22 Ru/mL (POD 8)NA--PMTMCT33Kaylie (32)46FTemporal bone120CTNANANA--PMTMCT34Inokuchi (33)24FRight nasal cavity and paranasal sinuses4CT484 Ru/mL (N: 32--84)58 Ru/mL (POD 3)No--Hemangiopericytoma35Yoshioka (34)45MClivus10MRINA49 pg/mLRecurrenceAfter first surgery received RT followed by medical management. Octreotide was not effective.Hemangiopericytoma36Koriyama (35)41FRight maxillary sinus36CT309 pg/mL (N: 10--50)50 (2 h post surgery)No--PMTMCT37Elston (36)69FSkull84Octreoscan67 RU/mL (N: 3--45)32 RU/mL (3--45) (POD 0)No--PMTMCT38Beech (37)42MRight ethmoid sinus84MRINANANo--Hemangiopericytoma39Ahn (38)61MLeft lower buccal vestibule17PENANANo--Hemangiopericytoma40Uramoto (39)48MTongue24CTNANARecurrenceSecond surgery, RT\
Malignant PMTMCT41Lewiecki (40)46MMandible24Octreoscan262 RU/mL (N \<180)UD (POD 10)No--PMT42Kenealy (41)79FLeft ethmoid sinusNACT355 U/mL (N: 3--45)NANA--PMTMCT43Kenealy (41)40FLeft ethmoid sinus60Octreoscan484 U/mL (N: 3--45)NANA--Hemangiopericytoma44Kyoung-In Yun (42)71FMandible108PENANANo--Hemangiopericytoma45Woo (43)42FMandible108PE192 pg/mL (N: 1--71)98 pg/mL (POD 11)PersistencePatient on oral phosphate solution with close follow-up last FGF-23 92 pg/mLPMTMCT46Savage (44)73FLeft maxillary sinus84111In-pentetreotideNANANo--Hemangiopericytoma47Kurien (45)55MRight sphenoid, ethmoid sinus24CTNANANo--Hemangiopericytoma48Gupta (46)51MNasal cavity108FDG-PETNANANo--PMTMCT49Gore (47)52FNasal cavity48Octreoscan573 Ru/mL (N \<230)Normal (45 min post surgery)No--PMTMCT50Kobayashi (48)53FTemporal bone48SVS558.8 pg/mL (N: 4--54.3)Normal (POD 4)No--PMTMCT51Shelekhova (49)70FMaxillary sinusNAMRINANANA--PMTMCT52Shelekhova (49)53MFrontal sinusNACTNANANA--PMTMCT53Pedrazzoli (50)37FRight maxillary sinus32CTNANANo--Hemangiopericytoma54Mori (51)42MLeft maxillary alveolus36MRI241 pg/mL (N: 10--50)Normal (1 h post surgery)No--PMTMCT55Parshwanath (52)42FLeft nasal cavity and ethmoid sinus42CTNANANo--PMT56Battoo (53)34FLeft nasal cavity60PENANANA--Giant cell tumor57Peterson (54)33FMaxillary sinusNANANANANA--PMT58Peters (55)22MRight temporal lobe mass96PENANAPersistenceThree craniotomies with angioembolization, RT, PRRT, octreotide, dasatinibHemangiopericytoma59Akhter (56)52MC5 vertebraeNAFDG-PETNANANo--PMTMCT60Xian-Ling (57)43FRight petrous apex48MRINANAPersistenceOctreotide therapy\
PMTMCT61Xian-Ling (57)42FLeft ethmoid sinus24OctreoscanNANANo--PMTMCT62Guglielmi (58)22MLeft ethmoid sinus24OctreoscanNANAPersistenceRepeat surgery\
Hemangiopericytoma63Uno (59)53FRight temporal bone48CT\>200 (N: 10--50 pg/mL)\<50 (POD-2)NA--PMT-MCT64Uno (59)61MLeft basi frontalis60CT400 (N: 10--50 pg/mL)\<3 pg/mL (immediately)PersistenceRepeat surgery\
PMT-MCT65Andreupoulou (60)63MLeft frontal lobeNASVS156 pg/mL101 pg/mL (6 months post RT)At 6 months, patient had declining FGF-23--PMTMCT66Bergwitz (61)56MMandible228PE870 Ru/ml (N \<180)NAPersistenceMultiple surgeries, cinacalcet\
Ameloblastic fibrosarcoma67Monappa (62)35MRight mandible36PENANANo--PMTMCT68Chokyu (63)57MMiddle cranial fossa24MRI84 pg/mL (N: 10--50)14 pg/mL (POD 7)No--PMT69Chiam (64)55MRight nasal cavity18MRI232 RU/mL (N \<180)18RU/mL (\<180) day 5No--PMTMCT70Cho (65)47FNasal cavity, ethmoidal sinus36CTNANANo--Hemangiopericytoma72Brandwein-Gensler (67)66FNasal cavity, maxillaNAPENANANo--Glomangiopericytoma73Munoz (68)60MPosterior neck24FDG-PET575 RU/mL (N \<180)NormalNo--PMTMCT74Chang (69)37mLeft nasal cavity60PENANANo--Hemangiopericytoma75Jiang (70)38FMandible24OctreoscanNANANo--PMT-MCT76Jiang (70)69FMandible240Octreoscan393 pg/mL (N: 10--50)8No--PMT-MCT77Jiang\
(70)28MMandible48OctreoscanNANANo--Odontogenic fibroma78Jiang (70)56FMandible120OctreoscanNANANo--PMT-MCT79Jiang (70)55FLower gingiva204OctreoscanNANANo--PMT-MCT80Jiang (70)45FMandible132OctreoscanNANANo--Odontogenic fibroma81Jiang (70)50FMandible36OctreoscanNANANo--PMT-MCT82Jiang (70)27MMaxilla72OctreoscanNANANo--Odontogenic fibroma83Jiang (70)49FNasal sinus72OctreoscanNANARecurrenceObservationPMT-MCT84Jiang (70)24MNasal sinus48OctreoscanNANANo--PMT-MCT85Jiang (70)45FNasal sinus120OctreoscanNANANo--PMT-MCT86Jiang (70)57FNasal sinus102OctreoscanNANANo--PMT-MCT87Fatani (71)58MFloor of mouth, mandible240CTNANARecurrenceMultiple surgeries, wedge lung resectionMalignant PMTMCT88Mathis (72)28FCribriform plate36MRINANANo--PMTMCT89Mathis (72)32MAnterior cranial fossa, ethmoid sinus12CTNANAPersistenceMultiple surgeries\
PMTMCT90Tarasova (73)60FLeft frontal mass48SVS132 pg/mL (N: 10--50)134 Ru/mL (N \<180) (3 years after RT)No--NA91Papierska (74)40NARight maxillary sinusNAOctreoscan260.4 Ru/ml (N: 5-105)NANA--Glomangiopericytoma92Lee (75)60FRight maxillary sinus72CTNANANo--Glomangiopericytoma93Allevi (76)FRight maxillary sinusOctreoscanNANANo--PMT hemangiopericytoma94Annamalai (77)49MLeft nasal cavity180FDG-PET/DOTA224.5 RU/mL (N \<150)64.6 RU/mL (POD 2)No--PMTMCT95Okamiya (78)35FLeft ethmoid sinus8FDG-PET147 pg/mL (N: 14--40)16 pg/mLNo--PMTMCT96Arnaoutakis (54)50FRight ethmoid sinus6PENANANA--PMT97Mok (79)48MRight maxillary sinus12MRINANANo--PMT98Fernández-Cooke (80)3MMaxilla and mandible6PE395.1 pg/mL (N \<40) 1267.2 RU/ML (N \<60)NormalPersistenceRFA, Local steroid infiltration, calcitonin, bisphosphonates, propranolol, cinacalcetCentral giant cell granuloma99Fathalla (81)49FRight frontal lobe36Octreoscan609 RU/mL (N: 0--180)NANo--PMTMCT100Ray (82)35MLeft nasal cavity24CT5 X NNANo--Hemangiopericytoma101Qari (83)60MGingiva of mandibular teeth72PENANANo--PMT102Wasserman (84)50MC3 vertebrae24NANANANo--PMTMCT103Wasserman (84)33FNose, lips, tongue120NANANAPersistenceNAMalignant PMTMCT104Mani (85)56MOccipital bone36PENANANo--PMTMCT105Yu (86)37MMaxilla36PE129.97 pg/mL (N: 33.9--51.6)64.9 pg/mLNo--PMTMCT106Yu (86)50MMandible6PE312.84 pg/mL (N: 33.9--51.6)NANo--Spindle cell tumor with PMT features107Yu (86)50MLeft nasal cavity72Octreoscan272.71 pg/mL (N: 33.9--51.6)5.93 pg/mLNo--PMTMCT108Yu (86)38FLeft nasal cavity and ethmoid sinus12Octreoscan350.9 pg/mL (N: 33.9--51.6)NANo--PMTMCT109Takashi (87)77MLeft parotid gland96FDG-PET186.9 pg/mL6.5 pg/mLNo--PMTMCT110Gresham (88)42MEthmoid mass36MRINANANo--Glomangioma111Agaimy (89)48MNasal cavityNANANANA--Cellular, nondescript112Lee (90)33MRight mandible156Ga-DOTANOC86.7 pg/mL (N: 10--50)NANo--Giant cell granuloma113Lee (90)52MLeft ethmoid sinus6Ga-DOTANOC492.3 pg/mL (N: 10--50)NAPersistenceRTPMT114Schober (91)59FRight fronto-basal region22SVS1600 Ru/mL (N: 26--110)74 Ru/mLRecurrenceRepeat surgery\
Meningioma115Zuo (92)NAMLeft nasal cavity36OctreoscanNANANo--PMT116Zuo (92)NAFLeft maxillary bone36FDG-PETNANANo--PMT117Hana (93)38MBilateral ethmoid sinus84MRI120 pg/mL (N: 10--50)ND (POD-1)PersistenceRepeat surgeryPMTMCT118Chanukya (94)31MLeft nasal cavity24Ga-DOTANOC1310 Ru/mL (N: 0--150)109 Ru/mL (1 month post surgery)No--Hemangiopericytoma119Gonzalez (95)42MNasofrontal sinus72PE75.9 pg/mL (N: 8--54)8.4 pg/mLNo--PMTMCT120Singh (96)67MPosterior wall of mastoid antrum204Ga-DOTANOC237 Ru/mL (N: 0--150)NANA--PMT121Singh (96)45MLeft side of body of mandible12Ga-DOTANOC1553 Ru/mL (N: 0--150)NANA--PMT122Pelletier (97)37MMandibleNASVS f/b MRI310 Ru/mL (N: 19--114)NANA--NA123Pelletier (97)49FMandibleOctreoscan of growing lesion on MRI with FDG-avidity and gradient on SVS1194 Ru/mL (N: 19--114)200 Ru/mLPersistenceNANA125Villepelet (99)41FRight ethmoid sinusNACTNA48 pg/mL (POD-5)No--PMT126Pelo (100)62FLeft TMJ60PENANANo--PMT127He (101)54FRight parotid24Ga-DOTANOCNANANA--Salivary basal cell adenoma128Wu (102)49FRight mandible216NANANAPersistenceMultiple surgeriesOdontogenic fibroma129Wu (102)20FLeft maxilla48NANANANo--Odontogenic fibroma130Wu (102)30FRight maxilla60NANANANo--PMT of mixed epithelial & connective tissue type131Wu (102)36MLeft mandible60NANANANo--PMT of mixed epithelial & connective tissue type132Wu (102)25MRight maxilla72NANANANo--PMT of mixed epithelial and connective tissue type133Wu (102)15FRight mandible24NANANANo--PMT of mixed epithelial and connective tissue type134Wu (102)41MRight mandible60NANANANA--PMT of mixed epithelial and connective tissue type135Wu (102)34MLeft maxilla72NANANANo--PMT of mixed epithelial and connective tissue type136Wu (102)50MRight mandible18NANANANo--PMT of mixed epithelial and connective tissue type137Wu (102)66MRight maxilla108NANANANo--PMT of mixed epithelial and connective tissue type138Wu (102)26MLeft maxilla36NANANANo--PMT of mixed epithelial and connective tissue type139Wu (102)32MRight maxilla36NANANANo--PMT of mixed epithelial and connective tissue type140Wu (102)41MRight mandible60NANANANo--PMT of mixed epithelial and connective tissue type141Wu (102)22MRight mandible24NANANANo--PMT of mixed epithelial and connective tissue type142Wu (102)31MRight maxilla36NANANANo--PMT of mixed epithelial and connective tissue type143Wu (102)51MLeft mandible132NANANANo--PMT of mixed epithelial and connective tissue type144Wu (102)75MRight mandible72NANANANo--PMT of mixed epithelial and connective tissue type145Ding (103)66FRight nasal cavity48Ga-DOTATATENANANA--NA146Ding (103)41MRight mandible108Ga-DOTATATENANANA--NA147Mishra (104)46MRight temporal lobe mass60Ga-DOTANOC1028 Ru/mL (N \<180)NANA--PMTMCT148Mishra (104)52FLeft skull base tumor24Ga-DOTANOC725 Ru/mL (N \<180)150 Ru/mL (3 months post-surgery)No--PMTMCT149Li (105)40FLeft nasal cavity12HistoryNANARecurrenceRepeat surgery twiceHemangiopericytoma150Acharya (106)42MRight mandible12FDG-PET332 Ru/mL (N \<180)53 Ru/mL (POD 54)No--PMTMCT151Kurien (107)39FRight nasal cavity24NA260 Ru/mL (N \<180)40 Ru/mLNo--PMTMCT152Kurien (107)36FLeft ethmoid sinus24NANA126 Ru/mLNo--PMTMCT153Kurien (107)51MMiddle turbinate36NA604 Ru/mL (N \<180)\<5 Ru/mLNo--PMTMCT154Kurien (107)44MMiddle turbinate48NA145 Ru/mL (N \<180)94.7 Ru/mLNo--PMTMCT155Kurien (107)55MPosterior ethmoid, sphenoid24NANANANo--PMTMCT156Kurien (107)37FAnterior ethmoid with intracranial extension36NA695 Ru/mL (N \<180)38 Ru/mLPersistenceRTMalignant PMTMCT157Kurien (107)62FNasal cavity, all PNS48NANA899 Ru/mLPersistenceObservationPMTMCT158Paul (108)54FLeft mandible24Ga-DOTATATE1094 Ru/mL (N \<180)369 Ru/mL (POD-5) 44 Ru/mL (4 months post-surgery)No--PMTMCT159Pal (109)28MMandibleNAGa-DOTATATE201 Ru/mL (N \<180)307 Ru/mLPersistentMedical managementHemangiopericytoma160Pal (109)52FRight nasal cavityNAGa-DOTATATE814 Ru/mL (N \<180)NANo--Arteriovenous hemangioma161Pal (109)36FLeft maxillary sinusNAGa-DOTATATE1239 Ru/mL (N \<180)NANo--PMTMCT162Pal (109)58MLeft nasal cavityNAGa-DOTATATE513 Ru/mL (N \<180)NANo--Hemangiopericytoma163Pal (109)36FLeft nasal cavityNAFDG-PET2467 Ru/mL (N \<180)NANo--Hemangiopericytoma[^2] Table 3Summary of literature review.ParameterValueNo. of patients with available dataAge (years) (mean ± [s.d.]{.smallcaps})46 ± 14160Sex81:81162Location of tumor % (no.)163 Paranasal sinuses43.7 (76) Mandible21.5 (34) Intracranial11.8 (19) Maxilla9 (13) Oral cavity6.2 (10) Skull1.2 (2) Parotid1.3 (2) Posterior neck1.3 (2) Cervical vertebra1.3 (2) Infratemporal fossa0.7 (1) Mastoid antrum0.7 (1) Thyroid0.7 (1)Local symptoms % (no.)44.1 (49)111Hypophosphatemic symptoms Muscle weakness % (no.)77.9 (106)136 Fractures % (no.)61.2 (68)111 Bone pains % (no.)100 (142)142 Bony deformities % (no.)25.7 (27)105Duration of symptoms (months), median (IQR)36 (24--72)139Biochemical profile S. Calcium (mg %) (mean ± [s.d.]{.smallcaps})8.9 ± 0.587 S. Phosphorus (mg %) (mean ± [s.d.]{.smallcaps})  Pre-op1.4 ± 0.4119  Post-op3 ± 0.762 S. Alkaline phosphatase (U/L) (median (IQR))313 (200--420)95 TMP/GFR (median (IQR))0.9 (0.6--1.3)39 TRP (median (IQR))61 (46.2--72.2)21 PTH (pg/mL) (median (IQR))55.9 (39.3--83.7)73 1,25 (OH)2 vitamin D3 (pg/mL) (median (IQR))18 (8.2--26.2)46FGF-23 (Pre-op) (median (IQR)) X ULN3.6 (1.8--6.8)55 C-terminal (Ru/mL)573 (234--1058)33 Intact (pg/mL)256 (131--393)22FGF-23 (Post-op) C-terminal (Ru/mL)69.3 (36.5--138)18 Intact (pg/mL)14 (5.9--50)15Tumor size (cm) (median (IQR))2.5 (1.8--3.2)70Localization imaging % (no.)131 History and PE16.7 (22) X-ray2.3 (3) CT scan25.9 (34) MRI10.6 (14) Octreotide scintigraphy20.6 (27) FDG-PET/CT8.4 (11) Ga-DOTA-based PET/CT11.4 (15) Selective venous sampling of FGF-233.8 (5)Primary modality of treatment % (no.)160 Surgery97.5 (156) Radiation therapy1.2 (2) Combined surgery + radiation therapy1.2 (2) Complete response to primary treatment % (no.)80.4 (119)148 Persistent disease % (no.)13.5 (20)148 Follow-up (months)13 (5.2--36)108 Recurrence % (no.)7 (9)128 Time to recurrence (months) (range)2--204Site wise persistence/recurrence % (no./no.) Paranasal sinuses14.4 (7/4)76 Mandible17.6 (6/0)34 Intracranial36.8 (4/3)19 Maxilla7.6 (1/0)13 Oral cavity33.3 (1/2)10 Thyroid100 (1)1Secondary modality of treatment % (no.)26 Surgery65.4 (17) RT30.8 (8) Chemotherapy7.7 (2) Cinacalcet7.7 (2) Octreotide7.7 (2) Radiofrequency ablation3.8 (1) PRRT3.8 (1) Others3.8 (1) Metastasis % (no.)2.7 (4)148Histopathology % (no.)158 PMTMCT48.7 (77) PMT ossifying fibroma like1.3 (2) PMT mixed epithelial and connective tissue type9.5 (15) Malignant PMTMCT3.2 (5) Hemangiopericytoma22.8 (36) Giant cell tumor3.2 (5) Odontogenic fibroma3.2 (5) Glomangiopericytoma2.5 (4) Malignant schwannoma0.6 (1) Meningioma0.6 (1) Salivary basal cell adenoma0.6 (1) Ameloblastic fibrosarcoma0.6 (1) Primitive mesenchymal tumor0.6 (1) Arteriovenous hemangioma0.6 (1) Spindle cell tumor with PMT features0.6 (1) Cellular non-descript0.6 (1) Chronic inflammatory tissue with fibrosis and epithelial cell rests0.6 (1)

Out of 148 patients for whom outcome data were available; 119 patients had complete initial response to surgery, 20 patients had persistent disease and 9 patients had recurrence as defined by worsening of post-operatively documented normal biochemistry over a variable period of 2--204 months. Patients with persistent/recurrent disease (*n* = 29) were predominantly managed with surgery (65.3%) and/or radiotherapy (30.7%). Among these patients 11 were reported to be alive with no evidence of disease (ANED) and remaining patients were managed with phosphorus supplements with/without other treatment modalities. Four patients had metastatic disease with lymph node and/or lung metastasis. Histopathologically, PMTMCT (48.7%) remains the most commonly reported tumor type followed by hemangiopericytoma (22.7%), PMT of mixed epithelial and connective tissue type (9.4%), giant cell tumor (3.1%) and odontogenic fibroma (3.1%). Other rare types of tumor have been shown in [Table 3](#tbl3){ref-type="table"}.

Discussion
==========

TIO is a rare and underreported condition due to unawareness about the characteristic clinical and biochemical profile among treating clinicians. Through this study, we aim to highlight our experience with TIO cases involving head and neck region and provide a review of published literature analyzed on a per-patient basis. This will increase awareness and provide valuable insight on critical management issues for this rare diagnosis.

Cohort 1
--------

A significant time gap between initial presentation till diagnosis persists even in the presence of local symptoms ([@bib1]). For any atypical head and neck mass, clinician should enquire into history relevant to osteomalacia, and for a symptomatic patient appropriate biochemistry (S. calcium, S. phosphorus and alkaline phosphatase) should be requested. Vice versa, in a patient with non-localized TIO, a clinician should examine oral and nasal cavities for palpable swellings and enquire about relevant local symptoms.

At our center we carry out a complete biochemical evaluation for TIO which includes calcium studies (S. calcium, S. phosphorus, ALP), TMP/GFR, 1,25 (OH) vitamin D3 and FGF-23 levels. FGF-23 serves as a diagnostic marker as well as an indicator of residual disease or recurrence during long-term follow-up. Thereafter, functional imaging with Ga-DOTANOC PET/CT for localization is done. Its superiority compared to FDG-PET/CT is well established ([@bib110], [@bib111], [@bib112]). Functional imaging is followed by appropriate anatomic imaging to determine tumor extent and plan for surgical management. Alternatively, in a TIO patient presenting with local symptoms or a mass in head and neck region, anatomic imaging (CT/MRI) followed by biopsy can also be used.

Complete surgical removal with wide margin of excision remains the cornerstone of management in these cases ([@bib3]). This is particularly difficult in intracranial tumors resulting in persistent disease as noted in both our patients with intracranial tumors.

S. Phosphorus and FGF-23 levels are used for post-operative surveillance. Half-life of FGF-23 is very short and one can document it immediately post-operatively ([@bib93]). Persistent elevation of FGF-23 was noted post-operatively in two patients (cases 1 and 6), which normalized on re-evaluation after 3 months. This observation has been previously reported particularly with C-terminal FGF-23 assay ([@bib108], [@bib109]). Phosphate supplements are discontinued post-operatively to allow for surveillance. Reimaging is performed in patients with persistent symptoms and biochemically active disease.

In recurrent or persistent cases, complete tumor removal resulted in cure in two patients, hence, this remains the preferred approach at our institute. In inoperable cases, two patients received external beam radiotherapy (EBRT) and one patient received peptide receptor radiotherapy (PRRT). In one patient (Case 2) EBRT was given after first surgery due to difficult tumor location at petrous apex. He had a gradual and complete response to RT over next 4 years. In another scenario (case 3), the patient had persistent disease after functional endoscopic sinus surgery (FESS) for left ethmoid sinus tumor. Following two repeat FESS, patient was considered for EBRT for persistent disease. Patient received IMRT 54 Gy in 30 fractions. S. Phosphorus and FGF-23 normalized gradually over one and half years and this patient who was previously bedbound is now walking without any support.

One patient (case 5) in our cohort has received PRRT for persistent disease after two surgeries for base of skull tumor ([@bib113]). As tumor was Ga-DOTATATE avid having Krenning score IV, patient was considered for PRRT after a thorough discussion in a multidisciplinary meeting. This patient has stable disease after two cycles of PRRT with 150--200 uCi ^177^Lu-DOTATATE.

PMTMCT remains the commonest histopathologic entity in these patients. We also reported one patient for each of the following: PMT-OF like, odontogenic fibroma and hemangiopericytoma in our cohort. Detailed histopathological findings for cases three, four and six have been published previously (114).

Although the sample size of cohort 1 was small, the epidemiological data are similar to cohort 2. There is an increased prevalence of local symptoms at presentation and higher rate of persistence following primary surgery at our center. This could be attributed to referral bias to a tertiary care center.

Cohort 2
--------

Here we present a detailed review of published English literature for TIO cases involving head and neck region (*n* = 163) ([@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16], [@bib17], [@bib18], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23], [@bib24], [@bib25], [@bib26], [@bib27], [@bib28], [@bib29], [@bib30], [@bib31], [@bib32], [@bib33], [@bib34], [@bib35], [@bib36], [@bib37], [@bib38], [@bib39], [@bib40], [@bib41], [@bib42], [@bib43], [@bib44], [@bib45], [@bib46], [@bib47], [@bib48], [@bib49], [@bib50], [@bib51], [@bib52], [@bib53], [@bib54], [@bib55], [@bib56], [@bib57], [@bib58], [@bib59], [@bib60], [@bib61], [@bib62], [@bib63], [@bib64], [@bib65], [@bib66], [@bib67], [@bib68], [@bib69], [@bib70], [@bib71], [@bib72], [@bib73], [@bib74], [@bib75], [@bib76], [@bib77], [@bib78], [@bib79], [@bib80], [@bib81], [@bib82], [@bib83], [@bib84], [@bib85], [@bib86], [@bib87], [@bib88], [@bib89], [@bib90], [@bib91], [@bib92], [@bib93], [@bib94], [@bib95], [@bib96], [@bib97], [@bib98], [@bib99], [@bib100], [@bib101], [@bib102], [@bib103], [@bib104], [@bib105], [@bib106], [@bib107], [@bib108], [@bib109]). This is the largest series of its kind published to date.

Epidemiology
------------

As is the case with overall TIO literature, almost equal male:female ratio is reported in head and neck TIO patients ([@bib3]). Middle age is the most common age at presentation and three pediatric cases are reported so far. TIO is a difficult diagnosis in pediatric patients as heritable hypophosphatemic rickets is a more likely diagnosis unless the tumor is evident. Fernández-Cooke *et al.* have reported a 3-year-old child with rickets and a jaw tumor. Two years went by before a link was established between the two and a diagnosis of TIO was made ([@bib80]). In the case described by Reyes-Mugica *et al.* the heightened awareness of pediatric endocrinologist for this condition led to early screening with imaging and subsequent surgical removal resulting in cure within 6 weeks of onset of symptoms ([@bib25]). In the third case reported by Wu *et al.* also the duration of hypophosphatemic symptoms was 2 years ([@bib102]).

The time from symptom onset to final diagnosis remains dreadfully long. In this series of cases of TIO involving head and neck region, only 10% (*n* = 14) were diagnosed in the first year of disease onset with majority of them having local symptoms at presentation. Feng *et al.* observed a misdiagnosis rate of 95.1% with 240 case-times of misdiagnoses among 144 cases of TIO even in the presence of evident hypophosphatemia in 43.1% cases ([@bib115]). Reasons cited for misdiagnosis were disease rarity, insidious onset, nonspecific clinical manifestations and poor recognition by the clinician. Presence of local compressive symptoms and/or swelling in approximately 50% patients in this review highlights the problem of delayed or missed diagnosis as musculoskeletal symptoms are ignored until presentation with advanced local symptoms.

Biochemical profile
-------------------

The typical biochemical profile in TIO is straightforward: hypophosphatemia with normocalcemia, moderately elevated ALP, normal PTH, inappropriately normal-to-high urinary phosphate excretion, low serum 1,25 (OH)2 vitamin D3 and elevated FGF-23 levels ([@bib3]).

FGF-23 is useful as a tumor marker. Based on two case reports, half-life of FGF-23 is between 20--50 min ([@bib116], [@bib117]). More recently, Hana *et al.* reported half-life of FGF-23 to be 18.5 min in a patient with intracranial PMTMCT using intact FGF-23 assay ([@bib93]). This allows FGF-23 to be used for intraoperative monitoring to determine the extent of tumor removal. Immediate post-op decline in FGF-23 levels within normal range is reported by other investigators ([@bib36], [@bib47], [@bib51], [@bib59]) as well. Elston *et al.* reported discordant increase in C-terminal FGF-23 post-op which has not been confirmed by other studies ([@bib36]). As previously stated, persistent elevation in C-terminal FGF-23 in immediate post-operative period has been documented despite complete tumor removal ([@bib108], [@bib109]). With no reports on levels of other postulated phosphotonins like matrix extracellular phosphoglycoprotein (MEPE) and secreted frizzled-related protein 4 (SFRP4) in patients with TIO, their role still remains unclear ([@bib118]).

Location of tumor
-----------------

Most common site for TIO in head and neck region is paranasal sinuses. Among them, ethmoid sinuses are the most common site followed by maxillary, sphenoid and frontal sinuses. Most common tumors are PMTMCT, hemangiopericytoma and glomangiopericytoma, in descending order. The second most common site is bony tumors arising from the mandible and maxilla with odontogenic fibroma and, PMT of mixed connective tissue and epithelial components as special tumor types. Third position is for intracranial tumors involving anterior cranial fossa, middle cranial fossa, and posterior cranial fossa, in descending order of prevalence. Reported tumors include PMTMCT, hemangiopericytoma and meningioma. Tumors of oral cavity include gingival tumors (molar/premolar), tongue and buccal vestibule in that order of occurrence. Apart from PMTMCT (including malignant) and hemangiopericytoma, tumors from this region also include giant cell tumor and ossifying fibroma. Rarely tumors have been reported from skull, parotid glands, posterior neck, infratemporal fossa, mastoid antrum, thyroid and vertebra.

Localization imaging
--------------------

Classically, history of local compressive symptoms and/or visible mass on physical examination is instrumental in diagnosing TIO even in this current era of sensitive imaging modalities. Earlier clinicians were dependent on physical examination and x-rays for diagnosing TIO. Renton *et al.*, Nitzan *et al.*, and Nomura *et al.* have localized head and neck TIO through x-rays alone ([@bib5], [@bib7], [@bib8]). With the introduction of CT scans (1980--2000), 60% tumors in the head and neck region were localized with this modality. The first localization of head and neck TIO on MRI was reported by Avila *et al.* in 1996 using MR skeletal survey ([@bib19]).

Following *in vitro* demonstration of somatostatin receptors (SSTRs) by Reubi *et al.* ([@bib119]), scintigraphic studies using ^111^In-pentetreotide for tumor localization was published by De Beur *et al.* in 2002 ([@bib120]). Subsequently, localization with ^99^mTc-MIBI and FDG-PET scans was reported ([@bib121], [@bib122]). Use of FDG-PET was limited due to poor specificity of non-receptor-based imaging, and slow-growing nature of these tumors resulting in false-negative results ([@bib96]). With improved spatial resolution, lower radiation dose and more rapid whole-body tomographic imaging of PET/CT studies in comparison to scintigraphy, ^68^Ga-DOTA-based PET/CT scans became the investigation modality of choice in TIO patients ([@bib112], [@bib123]). Various studies have shown superiority of ^68^Ga-DOTATATE PET/CT and ^68^Ga-DOTANOC PET/CT over FDG-PET/CT and Octreoscan for tumor localization in TIO ([@bib110], [@bib111], [@bib112]). The largest such study is that of 54 patients by Zhang *et al.* using ^68^Ga-DOTATATE PET/CT reported 100% sensitivity and 90.9% specificity in lesion detection ([@bib124]). Use of positron emitter radiotracer ^68^Ga enabling PET-based imaging along with higher affinity SSTR ligands like DOTATATE (SSTR 2\>5) and DOTANOC (SSTR 2,3,5) are postulated to be responsible for enhanced sensitivity of ^68^Ga-DOTA-based PET/CT over Octreoscan ([@bib112]). Thereafter, Singh *et al.* highlighted the issue of multiple low-grade benign uptakes using ^68^Ga-DOTANOC PET/CT especially at fracture sites and described the use of SUVmax and anatomical imaging showing soft tissue component in the lesion to pinpoint the causal lesion ([@bib96]). In summary, Ga-DOTA-based PET/CT is superior to other functional studies like FDG-PET and Octreoscan, but its utilization will depend on local availability and expertise ([@bib119]).

Selective venous sampling of FGF-23 has been studied for accurate localization of TIO. Kobayashi *et al.* used selective venous sampling as an initial guiding modality localizing the tumor to right head and neck region, although on retrospect distortion of right external ear canal was noted and no prior functional imaging was done to localize the tumor ([@bib48]). Andreopoulou *et al.* reported sensitivity of 87% and specificity of 71% at FGF-23 concentration ratio of 1.6 between the venous drainage of the tumor bed and general circulation after sampling 17 major veins and their branches ([@bib60]). They concluded that selective venous sampling is not useful in the absence of suspicious lesion on imaging studies and its use should be limited to cases with multiple suspicious sites or before resection in anatomically challenging cases. In 2017, Lee *et al.* reported contrasting results. In their cohort, five patients negative on both ^111^Indium-octreotide scintigraphy and FDG-PET/CT were subjected to selective blood sampling from 10 to 14 sites ([@bib90]). They identified the culprit lesion on follow-up with targeted MRI or whole-body Ga-DOTATOC in four patients. Tarasova *et al.* and Shober *et al.* have used selective venous FGF-23 sampling to confirm the SSTR expressing meningioma to be the FGF-23 secreting culprit lesion as many meningiomas are avid on SSTR-based imaging but may not be the source of FGF-23 ([@bib73]). In summary, in the current era of SSTR-based imaging, the role of this modality seems to be limited to cases with multiple suspicious uptake sites, intracranial lesions consistent with meningioma, and lastly in imaging negative cases to identify a target for focused follow-up imaging.

Treatment
=========

Primary modality
----------------

Complete surgical resection with adequate wide margin remains the treatment of choice in these tumors ([@bib3]). This is supported in head and neck TIO cases where anatomical sites less amenable for this approach have higher persistence or recurrence rate for example intracranial tumors. Hana *et al.* also reiterated this principle in their report on recurrent anterior skull base tumor with enbloc tumor removal followed by filling of the large skull base defect with pedicle subgaleal flap resulting in absence of recurrence over 25-month follow-up ([@bib93]).

Stereotactic radiotherapy has been described in two cases as primary modality. Both patients had frontal lobe tumors and both refused surgery. One patient had lower plasma FGF-23 and oral phosphorous requirement at 6-month follow-up. The details of RT are not described in this case report ([@bib60]). The second patient received 60 Gy of fractionated stereotactic radiotherapy over 5 weeks ([@bib73]). On follow-up, patient was off phosphorus supplement and had normal FGF-23 concentration after 4 years. The tumor was stable with areas of multiple small hemorrhages. BMD improved by approximately 50% with no evident new fracture. As the tumors are slow growing, radiotherapy is deemed to be less effective ([@bib3]).

Surgery combined with adjuvant post-op radiotherapy was used by John *et al*. in a case of invasive 'malignant schwannoma' ([@bib27]). Over 2.5 years of follow-up, serum phosphorus normalized but 1,25(OH) vitamin D3 was persistently low. MRI showed no evidence of residual/recurrent tumor. Similarly, Lee *et al.* described a case where the patient received post-operative radiotherapy following incomplete removal of an ethmoid tumor, which resulted in normal serum phosphorus with no residual tumor on MRI after completion of RT ([@bib90]).

In summary, although complete surgical excision remains the treatment modality of choice, in rare cases radiation therapy can be used with an expectant slow response.

Persistent/recurrent disease
----------------------------

Persistent/recurrent disease signifies failure of complete resection of the tumor after primary excision. This occurs more commonly in intracranial disease and oral cavity lesions where enbloc tumor removal is challenging and leads to higher surgical morbidity and complications. Serial biochemical follow-up is essential as true recurrences after complete biochemical resolution are known, but usually it is the recurrence of symptoms which brings the disease to surface.

After anatomic imaging to confirm the site of tumor recurrence, re-exploration of the surgical site along with attempted enbloc removal remains the preferred approach. Out of eleven patients with persistent/recurrent disease who have ANED on follow-up, eight have been treated with re-surgery alone.

In persistent cases multiple re-surgeries, radiotherapy, cinacalcet and octeotride have been used with limited success. Seufert *et al.* reported a patient with left thigh TIO localized on octreotide scinitigraphy having complete resolution of phosphaturia and normalization of serum phosphorus with 50--100 µg of octreotide thrice a day in preoperative setting ([@bib125]). However, this initial success has not been replicated in subsequent studies ([@bib34], [@bib126]). Extrapolating from patients with hypoparathyroidism with elevated FGF-23 and serum phosphorus levels, Gellers *et al.* advocated for the use of cinacalcet in the treatment of TIO ([@bib127]). But development of hypercalciuria and hypocalcemia limits the use of cinacalcet in this cohort. Disease stability with dasatinib has been reported ([@bib55]). As these tumors also express SSTR, PRRT remains a potentially useful option in tumors showing Krenning III/IV uptake on ^68^Ga-DOTATATE PET/CT ([@bib113]). It has been more than a decade of successful utilization of two radiopeptides ^90^Y-DOTATOC and ^177^Lu-DOTATATE for treatment of advanced neuroendocrine tumors (NETs) ([@bib128]). After binding to SSTR these peptides are internalized in tumor cells and the released breakdown products in lysosomes mediate radioactivity-induced local damage ([@bib128]). Apart from our case, we could not find any other experience with PRRT in TIO literature. In patients with persistent disease, treatment with oral phosphate supplements and calcitriol is continued for symptomatic improvement.

Metastases
----------

Four cases of malignant TIO in head and neck region are reported so far. Three of them originated from oral cavity and one from mandible. Uramoto *et al.* described a case of malignant PMTMCT involving tongue with lymph node metastases treated with two surgeries followed by radiation therapy with persistent disease on last follow-up ([@bib39]). Bergwitz *et al.* reported a patient with ameloblastic fibrosarcoma of mandible with pulmonary and lymph node metastases ([@bib61]). Patient had multiple recurrences and was managed with repeated surgeries, and lastly cinacalcet with persistent hypophosphatemia. Fatani *et al.* reported an interesting case of malignant PMTMCT arising from oral cavity who after 17 years of follow-up developed lung metastases which were resected in addition to multiple surgeries for primary disease ([@bib71]). Patient was normophosphatemic on follow-up. The fourth case of malignant PMTMCT was reported by Wasserman *et al.* ([@bib84]). The tumor involved nose, lip and mouth. No further follow-up/management details have been reported.

Histopathology
--------------

Weidner *et al.* initially proposed the term phosphaturic mesenchymal tumors (PMT) and their classification into four distinct subtypes: (I) mixed connective tissue variant (MCT), (II) osteoblastoma like, (III) Non-ossifying fibroma type, (IV) ossifying fibroma like ([@bib129]). In 2004, Folpe *et al.* reviewed all previously published cases and found that they all belong to PMTMCT category ([@bib10]). In this review we have reported the revised diagnosis as mentioned by Folpe *et al.* In 2018, Wu *et al.* described a new entity called "PMT mixed epithelial and connective tissue type" which is found exclusively in alveolar bone of maxilla and mandible ([@bib102]). They found this tumor to be common in males and in patients \<40 years of age. They have proposed a revised diagnosis of previously published six cases to this new entity, but we have reported them according to the original report. Apart from PMTs, other reported tumors in head and neck region causing TIO include meningioma, salivary basal cell adenoma, malignant schwannoma, ameloblastic fibrosarcoma, and spindle cell tumor with PMT features.

Study limitations
-----------------

To our knowledge this is the largest review of TIO due to tumors located in head and neck region till date. The per-patient analysis method used in this study with minute detailing of all clinically relevant published aspects is the major strength of this study. There are several limitations in this study. As the review is a retrospective analysis of published case reports, all the limitations pertaining to retrospective studies apply to it. Additionally, many case reports lacked important clinical details as majority of them focused on pathology or imaging. A meticulous attempt was made to include all published literature regarding the subject but a few studies may not have been included.

Summary
-------

TIO in the head and neck region is a rare disorder that warrants management by a multidisciplinary team including an endocrinologist, head and neck surgeon, radiologist, nuclear physicist and pathologist. Low phosphorus with elevated FGF-23 levels in a patient with clinical features of osteomalacia and/or mass in the head and neck region should be evaluated with Ga-DOTA-based PET/CT imaging. An alternative approach would be anatomical imaging followed by biopsy in a patient with local symptoms and clinically apparent swelling. Complete surgical excision with wide margin is of utmost importance in these cases resulting in dramatic clinical and biochemical normalcy. Clinical and biochemical follow-up is necessary even after documented cure as true recurrences have been reported. Whenever complete excision is not achieved, repeat surgical excision is recommended for accessible disease burden. In inoperable cases, radiotherapy, PRRT and medical management are suitable alternatives which should be decided by a multidisciplinary team on an individual basis. Although the tumor remains benign in most cases, one must remain vigilant in case of long-standing disease due to the reported risk of metastasis. Histopathological examination in most cases reveals PMTMCT, but other types are also seen.
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[^1]: F, fractures; FESS, functional endoscopic sinus surgery; IMRT, intensity-modulated radiation therapy; MW, muscle weakness; NA, not available; OF, ossifying fibroma like; P, pain; PE, physical examination; PMTMCT, phosphaturic mesenchymal tumor mixed connective tissue type; PRRT, peptide receptor radionuclide therapy; RT, radiation therapy.

[^2]: F, female; M, male; N, normal value; NA, not available; OF, ossifying fibroma like; PE, physical examination; PMTMCT, phosphaturic mesenchymal tumor mixed connective tissue type; POD, post-op day; PRRT, peptide receptor radionuclide therapy; RT, radiation therapy; SVS, selective venous sampling of FGF-23; UD, undetectable.
